Overview

Clemastine Treatment in Individuals With Williams Syndrome

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Sheba Medical Center
Collaborator:
Tel Aviv University
Treatments:
Clemastine